CALGARY, Alberta, June 24, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage pharmaceutical company focused on the development of novel epigenetic combination ...
Zenith Epigenetics Announces Grant of U.S. Food and Drug Administration Fast Track Designation for ZEN-3694 in NUT Carcinoma Calgary, Alberta--(Newsfile Corp. - July 14, 2025) - Zenith Epigenetics Ltd ...
Zenith Epigenetics Ltd. (Zenith), a wholly owned subsidiary of Zenith Capital Corp., announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to ZEN-3694 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results